Middle Market Debt Weekly: Lenders Tighten Credit Protocols as Fed Pause & First Brands Fallout Expose Market Fragility

Private credit fraud allegations collide with Fed’s final rate cut as liquidity strains emerge

The week ending November 2, 2025, exposed deepening fault lines in middle market lending as the Federal Reserve delivered its second consecutive rate cut of the year—lowering the target range to 3.75%-4.00%—while Chair Jerome Powell signaled a potential pause amid resilient private sector employment and persistent inflation concerns.¹ This cautious policy stance coincided with explosive fraud allegations in First Brands Group’s bankruptcy, where lenders accused the $10 billion auto parts supplier of “widespread fraud” including misrepresentations in financial statements, credit agreements, and borrowing base certificates.² Meanwhile, record $50.35 billion usage of the Fed’s Standing Repo Facility on October 31 highlighted month-end liquidity pressures in banking markets, potentially constraining funding availability for middle market lenders despite official rate relief.³

Federal Reserve signals end of easing cycle amid mixed economic signals

The Federal Reserve’s October 29 decision marked 50 basis points of total cuts in 2025, with the 10-2 vote delivering a quarter-point reduction to 3.75%-4.00%.⁴ Powell emphasized a data-dependent approach rather than pre-committed easing, noting uncertainty remains elevated while highlighting labor market resilience. Market participants recalibrated accordingly, with futures pricing significantly reduced expectations for additional cuts in December following the announcement.⁵

For middle market borrowers, the rate reduction provides incremental relief on SOFR-based facilities, though the Standing Repo Facility’s record usage—$50.35 billion across two operations on October 31—revealed structural funding strains as banks managed volatile deposits and month-end regulatory requirements.⁶ The spike in repo borrowing, highest since the tool’s 2021 inception, created potential spillovers to commercial lending availability as lending rates shot up well over the 4% top end of the fed funds target range.

First Brands fraud allegations rock private credit foundations

The First Brands bankruptcy became the week’s defining credit event as unsecured lenders filed emergency motions on October 30 alleging systematic fraud, with new information indicating the business “made misrepresentations in numerous financial statements, credit agreements, and borrowing base certificates” beyond existing allegations of double-pledged assets.⁷ The lender group sought to have certain special purpose vehicles dismissed from the Chapter 11 case.

According to court filings, although the special purpose vehicles were supposed to always have cash in their bank accounts, First Brands informed lenders shortly before the bankruptcy filing “that those bank accounts had no cash in them.”⁸ The federal watchdog for corporate bankruptcies joined creditor demands for an independent investigation, with the US Trustee citing “serious allegations of fraud, dishonesty, incompetence, misconduct, or mismanagement” and noting the company admitted it cannot find $2.3 billion related to off-balance sheet financing deals.⁹

Wall Street firms now face significant exposure, with Jefferies holding $715 million in receivables through its Leucadia Asset Management funds, while UBS O’Connor’s working capital finance fund held 30% exposure to First Brands.¹⁰ The collapse intensifies scrutiny of private credit’s asset-based lending segments, where yield competition has driven funds toward complex auto finance structures. Federal prosecutors opened an investigation into the circumstances around First Brands’ collapse.¹¹

Healthcare M&A dominates middle market transaction flow

Blackstone and TPG agreed to acquire medical device maker Hologic for up to $18.3 billion including debt, with stockholders receiving $76 per share in cash plus a contingent value right of up to $3 per share based on revenue milestones for the company’s Breast Health business.¹² The October 21 announcement represents one of the year’s largest middle market healthcare transactions and a 46% premium to Hologic’s May 23 closing price. The transaction includes significant minority investments from Abu Dhabi Investment Authority and GIC.¹³

Novartis agreed on October 27 to buy Avidity Biosciences for $12 billion, paying $72 per share in cash—a 46% premium to the biotech’s October 24 closing price.¹⁴ The acquisition brings Avidity’s late-stage neuroscience pipeline into Novartis, including three antibody-oligonucleotide conjugates for rare neuromuscular diseases, with the deal expected to unlock multi-billion-dollar opportunities through planned product launches before 2030.¹⁵ Avidity will spin out its early-stage precision cardiology programs into a separate publicly traded company prior to closing.

These transactions underscore investor conviction in defensive healthcare sectors amid broader economic uncertainty, with private equity and strategic acquirers prioritizing assets with near-term revenue visibility and regulatory pathways.

Asset-based lending maintains selective growth amid fraud concerns

The revelations from First Brands prompted immediate protocol enhancements across ABL providers, with lenders accelerating adoption of AI-powered verification technologies and increasing field exam frequency for automotive-adjacent borrowers. Advance rates remained compressed at 80-85% on receivables and 45-50% on inventory as the industry absorbed lessons from high-profile failures.

Despite heightened scrutiny, specialized lenders demonstrated continued appetite for collateral-backed structures. The ABL market’s trajectory faces near-term headwinds from liquidity signals and fraud concerns, though the sector benefits structurally from banks’ continued retreat to prime credits and regulatory capital constraints that favor asset-based approaches over unsecured corporate lending.

BDC sector navigates restructuring surge

Lazard reported record third-quarter financial advisory revenue of $422 million, up 14% year-over-year, with CEO Peter Orszag noting strength across M&A in healthcare, industrials, and consumer sectors, as well as robust restructuring and liability management activity.¹⁶ Lazard’s restructuring practice engaged in mandates including debtor roles for First Brands Group, Altice France, and Grapevine Energy, alongside creditor roles for Anthology, CityFibre, and Saks Global.¹⁷

The uptick in restructuring work reflects mounting stress in leveraged portfolios, though Lazard CEO Orszag noted recent bankruptcies aren’t indicative of broader private credit systemic issues, with increased performance dispersion among firms allowing restructuring and M&A activities to coexist rather than move inversely as historically observed.¹⁸

Items to Consider

Validate Collateral Representations: First Brands allegations underscore the imperative for independent asset verification in private credit transactions, particularly those involving receivables factoring, inventory finance, and auto-related exposures. Third-party field exams and AI-powered invoice verification should transition from periodic to continuous monitoring.

Stress Test Funding Availability: Record repo facility usage signals potential bank funding constraints that could ripple through ABL and factoring liquidity. Middle market lenders should model scenarios where traditional funding lines experience quarter-end and month-end volatility, potentially requiring alternative capital sources or increased facility pricing.

Model Policy Pause Scenarios: Fed’s pause signal after two consecutive cuts requires refinancing plans incorporating stable-but-elevated SOFR-plus spreads rather than assumptions of continued easing. Borrowers approaching maturities should prioritize term extensions while credit remains accessible.

Prioritize Defensive Sectors: Healthcare M&A resilience—evidenced by the Hologic and Avidity transactions—suggests continued capital availability for companies with regulatory visibility and recurring revenue models. Cyclical industries facing tariff uncertainty may experience prolonged valuation pressure and reduced leverage capacity.

Enhance Fraud Detection Protocols: Traditional quarterly or semi-annual field exams prove insufficient in preventing large-scale fraud. Real-time borrowing base monitoring, automated collateral verification, and enhanced lender collaboration to identify double-pledging should become industry standard practices.

Conclusion

The week ending November 2, 2025, crystallized fundamental tensions across middle market finance: measured Fed accommodation meets explosive fraud revelations threatening private credit’s credibility, while record repo usage exposes banking system fragilities even as rates decline. First Brands’ collapse—with $2.3 billion in missing assets and allegations of systematic misrepresentation—forces rapid adaptation through enhanced verification protocols and collateral monitoring.

As policymakers signal the end of rate cuts amid economic resilience, middle market success increasingly depends on operational excellence and credit rigor rather than monetary tailwinds. The healthcare sector’s robust M&A activity demonstrates that capital remains abundant for quality assets with defensive characteristics, while restructuring advisors report sustained engagement across stressed credits. Lenders and borrowers alike must navigate an environment where yield-chasing has compromised underwriting discipline in segments of the market, making technology adoption and transparency paramount to maintaining market confidence and avoiding contagion from high-profile failures.

Footnotes

1. Federal Reserve issues FOMC statement
2. First Brands Lenders Allege ‘Widespread Fraud’ in Court Filing
3. Banks tap Fed Standing Repo Facility in record numbers
4. Fed rate decision October 2025
5. The Fed is likely to keep cutting interest rates
6. Banks tap Fed Standing Repo Facility in record numbers
7. First Brands Lenders Allege ‘Widespread Fraud’ in Filing
8. First Brands Lenders Allege ‘Widespread Fraud’ in Filing
9. US Seeks Independent Bankruptcy Probe of First Brands
10. First Brands Collapse Blindsides Wall Street
11. DOJ Probes First Brands’ Shock Bankruptcy
12. Hologic to be Acquired by Blackstone and TPG for up to $79 per Share
13. Blackstone, TPG Agree to $18 Billion Deal to Buy Hologic
14. Novartis Agrees to Buy Avidity in $12 Billion Biotech Deal
15. Novartis agrees to acquire Avidity Biosciences
16. Lazard Reports Third Quarter and Nine Month 2025 Results
17. Lazard Reports Third Quarter and Nine Month 2025 Results
18. Lazard Q3 2025 Earnings Call Highlights